Sinalização JAK/STAT
Os inibidores da sinalização JAK/STAT são compostos que interrompem a via da Janus quinase (JAK) e do transdutor e ativador da transcrição (STAT), que está envolvida na sinalização de citocinas, crescimento celular e resposta imunológica. Esses inibidores são ferramentas importantes para estudar a regulação dessa via e seu papel em diversas doenças, incluindo cânceres, distúrbios imunológicos e condições inflamatórias. Os inibidores de JAK/STAT também estão sendo desenvolvidos como terapias direcionadas para essas doenças. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de sinalização JAK/STAT de alta qualidade para apoiar sua pesquisa em biologia molecular, oncologia e imunologia.
Subcategorias de "Sinalização JAK/STAT"
Foram encontrados 321 produtos de "Sinalização JAK/STAT"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Neocucurbitacin A
CAS:<p>Neocucurbitacin A (compound 7), a STAT3 inhibitor extracted from the pericarp of Aquilaria crassna, serves as a potential agent for anticancer research [1].</p>Fórmula:C31H42O8Pureza:98%Cor e Forma:SolidPeso molecular:542.66SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Fórmula:C30H32N8O5SCor e Forma:SolidPeso molecular:616.69S-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Fórmula:C17H18N6Pureza:98%Cor e Forma:SolidPeso molecular:306.37PROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Fórmula:C55H69N13O7SPureza:98%Cor e Forma:SolidPeso molecular:1056.28TP-5801 TFA
<p>TP-5801 TFA is an orally active inhibitor of TNK1, a non-receptor tyrosine kinase, with an IC50 value of 1.40 nM, demonstrating anti-tumor activity [1].</p>Fórmula:C26H32BrF3N8O3Pureza:98%Cor e Forma:SolidPeso molecular:641.48Deuruxolitinib
CAS:<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Fórmula:C17H18N6Cor e Forma:SolidPeso molecular:314.41HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Fórmula:C60H69N17O11SCor e Forma:SolidPeso molecular:1236.36MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Fórmula:C23H26N4O2SCor e Forma:SolidPeso molecular:422.54KT-333 diammonium
CAS:<p>KT-333 diammonium functions as a molecular glue that targets and degrades the STAT3 protein. It selectively mediates the degradation of STAT3 via the ubiquitin-proteasome pathway by attaching to STAT3 and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). This compound exhibits strong specificity in degrading STAT3 and demonstrates significant antitumor activity. KT-333 diammonium is applicable in researching hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).</p>Fórmula:C60H80ClN12O14PSCor e Forma:SolidPeso molecular:1291.84KT-333 ammonium
CAS:<p>KT-333 ammonium (Compound A) acts as a molecular glue that targets and promotes the degradation of the STAT3 protein through the ubiquitin-proteasome system. This compound achieves selective degradation by binding simultaneously to the STAT3 protein and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). It exhibits strong selectivity and efficacy in degrading STAT3, possessing notable antitumor properties. KT-333 ammonium is particularly useful for research on hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) [1].</p>Fórmula:C60H77ClN11O14PSCor e Forma:SolidPeso molecular:1274.81TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Cor e Forma:SolidPeso molecular:404.16485Fulipiftide
CAS:<p>Fulipiftide is a short peptide derived from pigment epithelium-derived factor (PEDF). It stimulates the amplification of nuclear stem cell factor+TSPC by activating the ERK2 and STAT3 signaling pathways. Fulipiftide also exhibits anti-inflammatory properties and is applicable in research on acute tendon injuries.</p>Fórmula:C144H227N41O47Cor e Forma:SolidPeso molecular:3284.59DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Fórmula:C25H38N4O3Cor e Forma:SolidPeso molecular:442.59SD-2301
CAS:<p>SD-2301 is a PROTAC degrader of STAT3.</p>Fórmula:C64H80N13O15PS2Cor e Forma:SolidPeso molecular:1366.50WDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Fórmula:C29H31F3N4O4Cor e Forma:SolidPeso molecular:556.576Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Fórmula:C23H25F5N7O5PPureza:99.57%Cor e Forma:SolidPeso molecular:605.45STAT3-IN-41
<p>STAT3-IN-41 (Compound 16) is a prodrug of compound 1. It gradually releases compound 1, which inhibits the STAT3 signaling pathway. STAT3-IN-41 exhibits antitumor activity against lung cancer, hepatocellular carcinoma, and pancreatic cancer.</p>Fórmula:C22H30F3NO7Cor e Forma:SolidPeso molecular:477.471Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Cor e Forma:Odour SolidPROTAC STAT3 degrader-2
CAS:<p>PROTAC STAT3 degrader-2 selectively breaks down STAT3 (DC50: 3.54μM, Molm-16) with cancer research potential.</p>Fórmula:C59H60F2N9O13PCor e Forma:SolidPeso molecular:1172.13Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Cor e Forma:Odour SolidAtinvicitinib
CAS:<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Fórmula:C16H17FN6O3Pureza:99.36%Cor e Forma:SolidPeso molecular:360.35CHZ868
CAS:<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Fórmula:C22H19F2N5O2Pureza:99.38%Cor e Forma:SolidPeso molecular:423.42SD-436
CAS:<p>SD-436 is a selective and highly efficient STAT3 PROTAC degrader (DC50 = 0.5 μM), with an IC50 of 19 nM for STAT3, significantly higher than for STAT1/4/5/6. SD-436 depletes STAT3 and induces tumour regression in mouse leukaemia and lymphoma xenograft models.</p>Fórmula:C58H62F4N9O14PSPureza:99.34%Cor e Forma:SolidPeso molecular:1248.2DTP3
CAS:<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Fórmula:C26H35N7O5Cor e Forma:SolidPeso molecular:525.6Pim-1/2 kinase inhibitor 1
CAS:<p>Orally active Pim-1/2 inhibitor blocks kinase phosphorylation; used in prostate cancer research.</p>Fórmula:C11H9NO3SPureza:99.78%Cor e Forma:SolidPeso molecular:235.26Itacitinib adipate
CAS:<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Fórmula:C32H33F4N9O5Cor e Forma:SolidPeso molecular:699.66Ilunocitinib
CAS:<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Fórmula:C17H17N7O2SPureza:99.88%Cor e Forma:SolidPeso molecular:383.43AK-1690
CAS:<p>AK-1690 is a potent and selective STAT6 PROTAC degrader that induces degradation of STAT6 proteins in cells and depletes STAT6 proteins in mouse tissues.</p>Fórmula:C51H56F2N5O11PSPureza:99.95%Cor e Forma:SolidPeso molecular:1016.055,15-DPP
CAS:<p>5,15-Diphenylporphyrin (5,15-DPP) is a selective STAT3-SH2 antagonist with IC 50s of 0.28 μM and 10 μM for STAT3 and STAT1, respectively [1].</p>Fórmula:C32H22N4Cor e Forma:SolidPeso molecular:462.54Ifidancitinib
CAS:<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Fórmula:C20H18FN5O3Pureza:98.05%Cor e Forma:SolidPeso molecular:395.39FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Fórmula:C28H32O6Pureza:97% - 97.90%Cor e Forma:SolidPeso molecular:464.55Filgotinib
CAS:<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Fórmula:C21H23N5O3SPureza:98.03% - ≥95%Cor e Forma:SolidPeso molecular:425.5RGB-286638 free base
CAS:<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Fórmula:C29H35N7O4Pureza:98% - 99.91%Cor e Forma:SolidPeso molecular:545.63JAK3-IN-6
CAS:<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Fórmula:C19H18N4O3Pureza:99.94% - 99.94%Cor e Forma:SolidPeso molecular:350.37Ritlecitinib
CAS:<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Fórmula:C15H19N5OPureza:98.82% - 99.92%Cor e Forma:SolidPeso molecular:285.34SHR0302
CAS:<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Fórmula:C18H22N8O2SPureza:99.11%Cor e Forma:SolidPeso molecular:414.48AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Cor e Forma:Yellow SolidPeso molecular:294.3RO8191
CAS:<p>RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.</p>Fórmula:C14H5F6N5OPureza:98% - 98.85%Cor e Forma:SolidPeso molecular:373.21SMI-16a
CAS:<p>SMI-16a (PIM1/2 Kinase Inhibitor VI) , a cell-permeable thiazolidinedione compound, acts as an effective, ATP-competitive inhibitor against Pim-1/2 kinases (</p>Fórmula:C13H13NO3SPureza:99.99%Cor e Forma:SolidPeso molecular:263.31SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Fórmula:C21H18ClFN4O4Pureza:98.99% - 99.77%Cor e Forma:SolidPeso molecular:444.84XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Fórmula:C25H28N6O2Pureza:99.19%Cor e Forma:SolidPeso molecular:444.53Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Fórmula:C23H25ClFN7OPureza:99.33% - 99.86%Cor e Forma:SolidPeso molecular:469.94Momelotinib HCl
CAS:<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Fórmula:C23H24Cl2N6O2Cor e Forma:SolidPeso molecular:487.38Atractylenolide I
CAS:<p>Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.</p>Fórmula:C15H18O2Pureza:97.55% - 99.92%Cor e Forma:SolidPeso molecular:230.3TCS-PIM-1-4a
CAS:<p>SMI-4a, a Pim inhibitor, activates AMPK, halts mTORC1, and kills various myeloid/lymphoid cells (IC50=0.8-40μM).</p>Fórmula:C11H6F3NO2SPureza:99.89%Cor e Forma:SolidPeso molecular:273.23Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Fórmula:C18H22N4O2Pureza:98.67% - 99.4%Cor e Forma:SolidPeso molecular:326.39Tofacitinib Citrate
CAS:<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Fórmula:C22H28N6O8Pureza:99.19% - 99.75%Cor e Forma:SolidPeso molecular:504.49Gusacitinib HCl
CAS:<p>Gusacitinib (ASN-002/EN-3351), a potent SYK/JAK inhibitor, has strong antitumor activity in various cancers.</p>Fórmula:C24H29ClN8O2Cor e Forma:SolidPeso molecular:497Ruxolitinib (S enantiomer)
CAS:<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Fórmula:C17H18N6Pureza:99.37% - 99.79%Cor e Forma:SolidPeso molecular:306.36
